Krsnaa Diagnostics Reports 22% Revenue Growth in Q1 FY2027 as Rajasthan Pathology Network Goes Live

Krsnaa Diagnostics Reports 22% Revenue Growth in Q1 FY2027 as Rajasthan Pathology Network Goes Live​

Krsnaa Diagnostics Ltd., an integrated diagnostic service provider, announced its unaudited financial and operational results for the quarter ended June 30, 2026. The company reported a 22% year-on-year growth in revenue from operations, reaching ₹2,355 million.

The strong performance was driven by continued expansion in established business lines and contributions from newly commissioned projects across the network. Like-for-like projects saw approximately 12% YoY growth during the quarter.

Q1 Financial Performance Snapshot​

Operational Milestones and Expansion​

The company achieved several key operational milestones during the quarter, including making 8 out of 17 planned MRI centres in Maharashtra operational. Twelve new NABH accreditations were also added to the network. Furthermore, Apulki-Pune hospital commenced operations, and Krsnaa secured a new CT project award in Himachal Pradesh for 34 CT scanners.

Focus on Rajasthan Pathology​

The Rajasthan pathology network transitioned successfully from implementation into full operations during Q1 FY2027. By the end of the quarter, the operational infrastructure included 31 mother labs, 62 hub labs, and 1,228 collection centres, contributing ₹257 million in revenue for the quarter.

Management noted that the moderation observed in margins is primarily attributed to the upfront fixed cost base—including labor, equipment, manpower, and logistics associated with setting up the Rajasthan laboratories—which precede full utilization. This structure reflects an infrastructure led model where investment precedes revenue generation as utilization scales.

Retail Network Acceleration​

The retail segment demonstrated significant growth, reporting a 64% year-on-year increase and a 22% sequential rise, generating ₹193 million in revenue. The company expanded its retail network to exceed 4,250 touchpoints spanning five states.

Promoter Confidence and Platform Development​

The Board of Directors reaffirmed confidence in the platform's future by approving the issue of share warrants to the Promoter and Promoter Group, subject to applicable regulatory requirements.

Commenting on the results, Mr. Yash Mutha, Managing Director, stated that Q1 FY2027 highlights the growing strength of the existing business alongside the contributions from new projects in Rajasthan. He emphasized that with retail scaling rapidly and newly commissioned infrastructure moving toward higher utilization, the company remains focused on converting its platform into sustainable long-term value for shareholders.

Mr. Mitesh Dave, Group Chief Executive Officer, added that Q1 was a quarter defined by execution, successfully converting infrastructure into live revenue generating capacity. He noted that as utilization increases across these investments, the operating leverage inherent in Krsnaa's model is expected to become increasingly visible.

Krsnaa Diagnostics Ltd., which operates across 19 states and Union Territories, serves patients through its integrated diagnostic, technology, and logistics platform, encompassing both Radiology and Pathology services.

KRSNAA Stock Price Movement​

Krsnaa Diagnostics Limited shares slipped on Thursday, closing at ₹556.75 after shedding ₹15.80 and registering a 2.75% decline. The stock saw a trading volume of 83,070 shares during the session.